#1 Clinical Trials Search in Europe

Germanium (68Ge) Chloride

This article discusses the use of Germanium (68Ge) Chloride, a radiopharmaceutical generator, in clinical trials for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The drug is being studied as part of a diagnostic imaging technique to evaluate the effectiveness of treatment for liver metastases in GEP-NET patients. The trial aims to compare different methods of administering radiolabeled somatostatin analogs and assess their impact on tumor visibility and treatment outcomes.

Table of Contents

What is GERMANIUM (68GE) CHLORIDE?

GERMANIUM (68GE) CHLORIDE is an active substance used in a radiopharmaceutical product called Galliad[1]. Radiopharmaceuticals are special medicines that contain a small amount of radioactive material and are used for diagnostic or therapeutic purposes in nuclear medicine. In this case, Galliad is primarily used for diagnostic imaging.

Medical Use

Galliad, containing GERMANIUM (68GE) CHLORIDE, is used in the diagnosis and management of gastroenteropancreatic neuroendocrine tumors (GEP-NETs)[1]. These are rare tumors that occur in the digestive system and pancreas. The radiopharmaceutical helps in creating detailed images of these tumors, which is crucial for:

  • Detecting the presence and location of tumors
  • Assessing the spread of the disease, particularly to the liver
  • Monitoring the response to treatment
  • Planning further treatment strategies

Administration

Galliad is administered through intravenous use, which means it’s injected directly into a vein[1]. The maximum daily dose is typically around 200 MBq (megabecquerels), which is a unit used to measure radioactivity[1]. The administration is usually a one-time event for imaging purposes, lasting no more than one day.

Clinical Trial Information

A clinical trial is currently being conducted to explore new ways of using similar radiopharmaceuticals in the treatment of GEP-NETs[1]. While this trial doesn’t directly involve Galliad, it provides insight into how these types of drugs are being studied for both imaging and treatment purposes. The trial is investigating:

  • The use of intra-arterial hepatic (IAH) infusion of radiolabelled somatostatin analogs in patients with dominant liver metastases
  • Comparing the uptake of the radiopharmaceutical in liver metastases when administered through different routes (intra-arterial vs. intravenous)
  • The safety and efficacy of this approach in treating GEP-NETs

This research may lead to improved methods for both diagnosing and treating GEP-NETs in the future.

Safety and Precautions

As with all radiopharmaceuticals, there are important safety considerations when using Galliad[1]:

  • Radiation exposure: While the radiation dose is generally low and considered safe for diagnostic purposes, it’s important to follow the doctor’s instructions carefully.
  • Pregnancy and breastfeeding: These products are typically not recommended for pregnant or breastfeeding women due to potential risks to the fetus or infant.
  • Contraindications: Patients with certain medical conditions or those taking specific medications may not be suitable candidates for this imaging technique. It’s crucial to inform your healthcare provider about all your medical conditions and medications.
  • Post-procedure care: After the imaging procedure, patients may be advised to drink plenty of water to help flush the radiopharmaceutical from their system and to avoid close contact with pregnant women or young children for a short period.

Always consult with your healthcare provider for personalized information about the use of GERMANIUM (68GE) CHLORIDE or any radiopharmaceutical in your specific case.

Aspect Details
Drug Name Germanium (68Ge) Chloride (Galliad, 0.74 to 1.85 GBq, radiopharmaceutical generator)
Purpose Diagnostic imaging for gastroenteropancreatic neuroendocrine tumors (GEP-NETs)
Administration Intravenous use, compared with intra-arterial hepatic infusion
Maximum Daily Dose 200 MBq (megabecquerels)
Treatment Duration 1 day (for the imaging procedure)
Main Objective Compare 68Ga-DOTA-peptides uptake in liver metastases using different administration methods
Key Eligibility Criteria Adults with GEP-NETs, liver metastases, completed 4 cycles of LUTATHERA®

FAQ

  • What is Germanium (68Ge) Chloride used for in this clinical trial? Germanium (68Ge) Chloride is used as a radiopharmaceutical generator to produce a diagnostic imaging agent. It helps create 68Ga-DOTA-peptides, which are used in PET scans to visualize and measure the uptake of radiolabeled somatostatin analogs in liver metastases and other organs.
  • Who is eligible for this clinical trial? Eligible participants are adults (18 years or older) with histologically proven well-differentiated neuroendocrine tumors of gastrointestinal or pancreatic origin (GEP-NETs). They must have liver metastases that are dominant or exclusive, and have already received 4 standard cycles of LUTATHERA® treatment.
  • What is the main objective of this clinical trial? The main objective is to compare the uptake of 68Ga-DOTA-peptides in liver metastases when administered through intra-hepatic infusion versus intravenous injection. This is measured using PET scans and helps evaluate the effectiveness of different administration methods.
  • Are there any risks associated with participating in this trial? While specific risks are not detailed in the provided information, the trial does assess the safety profile of 177Lu-DOTA-peptide after intra-arterial hepatic administration. Participants must meet certain health criteria, including adequate kidney and liver function, to minimize potential risks.
  • How long does the treatment in this trial last? The trial involves a fifth cycle of 177Lu-DOTA-peptide therapy administered by intra-arterial hepatic infusion. The maximum treatment period is mentioned as 1 day, but follow-up evaluations may continue beyond this to assess efficacy and safety.

Ongoing Clinical Trials on Germanium (68Ge) Chloride

  • Evaluating 68Ga-FAPI-46 PET/CT Scanning for Improved Diagnosis in Patients with Pancreatic Cancer or Bile Duct Cancer Eligible for Curative Treatment

    Recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study of Intra-Arterial Infusion of Lutetium (177Lu) Oxodotreotide for Adults with Gastroenteropancreatic Neuroendocrine Tumors with Liver Metastases

    Recruiting

    2 1 1 1
    Investigated drugs:
    France

  • 68Ga-FAPI-46 PET-CT for Initial Staging of Gastric Cancer in Patients Eligible for Curative Treatment

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Gastroenteropancreatic neuroendocrine tumors (GEP-NETs): A type of cancer that forms in the hormone-producing cells of the digestive system, including the stomach, intestines, and pancreas.
  • Radiopharmaceutical: A drug that contains a radioactive substance used for diagnosing or treating diseases.
  • PET scan: Positron Emission Tomography, an imaging test that uses a radioactive tracer to show how organs and tissues are functioning.
  • Somatostatin analogs: Synthetic versions of the hormone somatostatin, used to treat certain types of neuroendocrine tumors.
  • SUVmax: Maximum Standardized Uptake Value, a measure used in PET imaging to show how much of a radiotracer is taken up by a specific area of the body.
  • Intra-arterial hepatic infusion: A method of delivering medication directly into the liver through the hepatic artery.
  • RECIST 1.1 criteria: Response Evaluation Criteria in Solid Tumors, a set of rules used to assess how well a cancer patient responds to treatment.
  • Metastases: The spread of cancer cells from the original tumor to other parts of the body.

References

  1. http://clinicaltrials.eu/trial/study-of-intra-arterial-infusion-of-lutetium-177lu-oxodotreotide-for-adults-with-gastroenteropancreatic-neuroendocrine-tumors-with-liver-metastases/